Open AccessPB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH‐RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT‐INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
Author(s) -
Zhuang Z.,
Tian Y.,
Shi L.,
Zou D.,
Feng R.,
Tian W.W.,
Yu H.,
Dong F.,
Liao A.,
Ma Y.,
Liu Q.,
Liu S.,
Jing H.,
Fu R.,
Ma L.M.,
Liu H.,
Sun W.,
Bao L.,
Wu Y.,
Chen W.,
Zhuang J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850984.40192.e8
Subject(s) - lenalidomide , bortezomib , thalidomide , multiple myeloma , medicine , dexamethasone , maintenance therapy , adverse effect , surgery , oncology , gastroenterology , chemotherapy